Results 251 to 260 of about 2,199,342 (345)

Cancer Screening Uptake and Usual Source of Care Among Hispanic Survivors of Adolescent and Young Adult Cancer. [PDF]

J Adolesc Young Adult Oncol
Choi E, Berkman AM, Andersen CR, Salsman JM, Betts AC, Milam J, Miller KA, Peterson SK, Lu Q, Cheung CK, Ghazal LV, Livingston JA, Hildebrandt MAT, Parsons SK, Freyer DR, Roth ME.   +15 more
europepmc   +1 more source

Determinants of male healthcare utilization in Switzerland: does gender identity and migration background matter? [PDF]

BMC Health Serv Res
Lieb M, Zaiser C, Laskowski NM, Müller R, Theunert M, Paslakis G.   +5 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Continuous Medicaid Eligibility, Child Insurance, and Health Care Use. [PDF]

Pediatrics
MacCallum-Bridges CL, Admon LK, Patrick SW, Kozhimannil KB, Daw JR.   +4 more
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Psychosocial predictors of non-adherence to antihypertensive medication among Korean adults: A nationwide cross-sectional study. [PDF]

PLoS One
Han K, Kim HS, Lee Y, Lee CW.
europepmc   +1 more source

Low‐intervention clinical trials in Spain: Do they progress?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza, Mayro J. Cortés Pestana, Kristopher Amaro, Rosa M. Antonijoan, Caridad Pontes   +4 more
wiley   +1 more source

Changes in PSA-Based Early Detection of Prostate Cancer over a 12-Year Period: Findings from the German KABOT Study. [PDF]

Healthcare (Basel)
Braun KP, Vogel T, May M, Gilfrich C, Herrmann M, Kravchuk AP, Maurer J, Wolff I.   +7 more
europepmc   +1 more source